Release date: 2016-04-14
In the business of the latest third-generation gene editing technology, CRISPR/CAs9 gene editing technology, there are three companies. In turn, Editas Medicine, founded by Zhang Feng et al; CRISPR Therapeutics, a Swiss drug research and development company founded by Emmanuelle Charpentier; and Intellia Therapeutics by Jennifer Doudna.
According to the US Securities and Exchange Commission (SEC) official website, on April 11, Intellia Therapeutics submitted a prospectus to the US SEC to propose an IPO of 120 million (120 million) dollars.
The earliest IPO CRISPR company - Editas Medicine
Editas current CEO Katrine Bosley
Founded in 2013, Editas Medicine (NASDAQ:EDIT) is a biotechnology company that is co-founded by MIT's Zhang Feng and Others. The current CEO is Katrine Bosley. It is a company that has made rapid progress in clinical trials in the field of genetic editing. It is planned to conduct a CRISPR experiment in 2017 to conduct human experiments on Leber congenital amaurosis (LCA; a hereditary vision loss disease). This will be the first time that CRISPR gene editing technology has been used in clinical trials; in collaboration with Juno, the cancer CAR-T treatment program, as well as benign blood diseases, hereditary muscle diseases, hereditary lung diseases, hereditary and infectious liver diseases.
On January 4, 2016, the company submitted the IPO prospectus to the SEC, and landed on Nasdaq on February 3, 2016, issuing 5.9 million shares at an issue price of $16-18 and raising $122 million. The stock code: EDIT. The stock price now fluctuates around $38.
The second company that specializes in CRISPR - CRISPR Therapeutics
Emmanuelle Charpentier
CRISPR Therapeutics is the second biotechnology company to focus on CRISPR technology. The company was founded in Switzerland and has relatively few online introductions and news. However, experts such as Nobel Laureate Craig Mello provided technical assistance to the company.
In October 2015, Vertex announced that it will pay 75 million in cash and 30 million in investment, and has signed a contract with CRISPR Therapeutics for four years to develop CRISPR-Cas9 drugs targeting human genetically proven targets, mainly Cystic pulmonary fibrosis and sickle anemia; if all projects are successfully listed, the final payment will be as high as $2.6 billion.
In December 2015, the company and Bayer jointly developed breakthrough therapy, which plans to invest US$300 million over the next five years to build a joint venture, relying on Crispr's advanced genetic technology - Crispr-Cas9 and Bayer's superb engineering protein technology. Breakthrough therapy to cure diseases such as hemophilia, blindness and congenital heart disease.
The second IPO's CRISPR company - Intellia Therapeutics
One of the founders of Intellia Therapeutics, CRISPR pioneer Jennifer Doudna
Founded in 2014, Intellia Therapeutics is focused on the development of CRISPR/Cas9 technology in the therapeutic field, such as leukemia, cancer, etc., and has received the first round of financing from Atlas Venture and Novartis.
Intellia Therapeutics product line
Intellia enjoys an extremely important intellectual property right in the field of CRISPR/Cas9 technology and has received the first round of financing from Atlas Venture and Novartis. The current chairman and CEO of the company is Dr. Nessan Bermingham. The future direction is to better integrate CRISPR and CAR-T.
In January 2015, the company launched a five-year R&D cooperation program with Novartis, a leader in the CAR-T field, to use the CRISPR genome editing technology to study diseases related to hematological stem cells (HSCs), including Systolic cell disease, beta-thalassemia, is dedicated to accelerating the development of CRISPR/Cas9 technology for CAR-T cell therapy and hematopoietic stem cells.
In September 2015, the company received $70 million in Series B financing.
On April 11, 2016, the company and Regeneron reached a six-year collaborative development protocol for CRISPR gene editing therapy. Regeneron paid $75 million in advance payments to the former and agreed to invest $50 million in Intellia's next round of equity financing. The two sides developed a total of 10 drugs during the cooperation period, and Regeneron can select 5 targets outside the field of liver disease.
Attachment: The rise of CRISPR technology and the company's list
Source: Bio-Exploration
Ivacaftor Intermediates,Synthetic Drug Lumacaftor,High Purity Vx 809,Cas 936727-05-8
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com